Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2019

View Archived Issues

In vivo research suggests E-cadherin drives metastasis

Bug likes bleach

Wharton's jelly-derived mesenchymal stem cells evaluated in chronic ischemic heart failure

GT Biopharma initiates enrollment in first-in-human study of GTB-3550

Navitor presents data from phase I program of NV-5138

Dahl-S model of hypertension associates higher cerebral blood flow with lower anxiety level

LCGA-17 peptide shows anxiolytic and antidepressant activity in zebrafish

BoNTANA Therapies describes nucleic acids encoding botulinum neurotoxins

CD47 single-domain antibodies patented by Shanghai Novamab Biopharmaceuticals

Adamed Pharma discovers dual 5-HT2A and 5-HT6 receptor antagonists

Fraunhofer-Gesellschaft identifies inhibitors of bacterial glutaminyl cyclases

New protein-arginine deiminase type-4 inhibitors synthesized at Nanjing TransThera Biosciences

Pharvaris announces financing to advance clinical development of HAE oral therapy

AgeneBio receives support for GABA-A alpha5 PAM program

Spinal SGK1 is involved in the development of morphine tolerance through NF-kB p65/NMDAR signaling

S100A9/TLR4 axis can be a target for the management of insulin deficiency

Red blood cell transfusions in anemic murine neonates cause necrotizing enterocolitis

CADPA multi-biomarker score identifies hidden risk of acute coronary syndromes

Phase I results of nivolumab, ipilimumab and nintedanib combination in advanced NSCLC presented

Study shows just how far precision target ID has yet to go

Phase III trial of Toca-511/Toca-FC in recurrent high-grade glioma misses primary endpoint

Ovid begins pivotal trial of OV-101 for Angelman syndrome

FDA approves Ibsrela for irritable bowel syndrome with constipation

ALK inhibitor PLB-1003 shows promising results in a phase Ia trial

ADC Therapeutics studies ADCT-301 for relapsed or refractory Hodgkin's lymphoma in phase II

Phase III study of CC-486 as maintenance therapy in AML meets primary and key secondary endpoints

Ritter's phase III trial of RP-G28 for lactose intolerance misses primary endpoint

Noxxon initiates phase I/II trial of NOX-A12 with radiotherapy for newly diagnosed brain cancer

Orion Biotechnology obtains Polish clearance to begin phase I study of microbicide gel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...